BRPI1009141A2 - composições e métodos para profilaxia e tratamento de vícios - Google Patents
composições e métodos para profilaxia e tratamento de víciosInfo
- Publication number
- BRPI1009141A2 BRPI1009141A2 BRPI1009141A BRPI1009141A BRPI1009141A2 BR PI1009141 A2 BRPI1009141 A2 BR PI1009141A2 BR PI1009141 A BRPI1009141 A BR PI1009141A BR PI1009141 A BRPI1009141 A BR PI1009141A BR PI1009141 A2 BRPI1009141 A2 BR PI1009141A2
- Authority
- BR
- Brazil
- Prior art keywords
- addictions
- prophylaxis
- compositions
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15937709P | 2009-03-11 | 2009-03-11 | |
US16782409P | 2009-04-08 | 2009-04-08 | |
PCT/US2010/027048 WO2010105103A1 (en) | 2009-03-11 | 2010-03-11 | Compositions and methods for prophylaxis and treatment of addictions |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1009141A2 true BRPI1009141A2 (pt) | 2016-03-08 |
Family
ID=42144781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1009141A BRPI1009141A2 (pt) | 2009-03-11 | 2010-03-11 | composições e métodos para profilaxia e tratamento de vícios |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP2405914A1 (pt) |
JP (1) | JP6163289B2 (pt) |
KR (2) | KR101767273B1 (pt) |
CN (2) | CN106692144A (pt) |
AU (1) | AU2010224037B2 (pt) |
BR (1) | BRPI1009141A2 (pt) |
CA (1) | CA2754901A1 (pt) |
MX (1) | MX2011009384A (pt) |
NZ (2) | NZ619408A (pt) |
WO (1) | WO2010105103A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013148572A1 (en) * | 2012-03-27 | 2013-10-03 | Albany Medical College | Blocking of cue-induced drug reinstatement |
CA2878402A1 (en) * | 2012-07-06 | 2014-01-09 | Omeros Corporation | Andrographis paniculata compositions and methods for treatment of addictions |
WO2015153263A1 (en) * | 2014-04-02 | 2015-10-08 | Yale University | Compositions and methods to treat addiction |
WO2019079327A1 (en) * | 2017-10-16 | 2019-04-25 | Falci Scott P | POLYTHERAPIES AND TREATMENT OF OPIOID DEPENDENCE BY ADMINISTRATION OF BRIVARACETAM OR LEVETIRACETAM AND OPIOID |
WO2020188361A1 (en) * | 2019-03-21 | 2020-09-24 | ZYUS Life Sciences US Ltd. | Cannabinoid and application supported opioid tapering |
CN110237069B (zh) * | 2019-07-09 | 2022-06-21 | 兰晟生物医药(苏州)有限公司 | 一种磷酸二酯酶4抑制剂的应用 |
EP3792252A1 (en) * | 2019-09-13 | 2021-03-17 | Red Bull GmbH | Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances. |
AU2021276656A1 (en) | 2020-05-19 | 2022-11-24 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
CN112229918A (zh) * | 2020-07-09 | 2021-01-15 | 中山大学 | Uplc-ms/ms法测定海洛因成瘾大鼠和小鼠体内代谢物在体内的分布及其应用 |
KR102333280B1 (ko) | 2021-07-05 | 2021-12-01 | 재단법인 산림힐링재단 | 행위중독예방 학습 스마트기기 및 그 제공방법 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6051189A (ja) | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
US4582839A (en) | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
CN1003445B (zh) | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | 噻唑烷二酮衍生物,其制备方法和用途 |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
JPH06779B2 (ja) | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | チアゾリジオン誘導体およびそれを含んでなる医薬組成物 |
US4812570A (en) | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
US6011049A (en) | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
WO2000073791A1 (en) | 1999-05-27 | 2000-12-07 | Tanabe Seiyaku Co., Ltd. | Remedies for kidney diseases and method for screening the same |
US6582738B2 (en) | 1999-09-13 | 2003-06-24 | Deseret Laboratories, Inc. | Process for preparing chewing gum containing a nutritional supplement |
AU2001247233A1 (en) | 2000-02-24 | 2001-09-03 | San Diego State University | Ppar gamma agonists for the treatment of liver inflammatory disorders |
GB0030845D0 (en) | 2000-12-18 | 2001-01-31 | Smithkline Beecham Plc | Novel treatment |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
JPWO2003016265A1 (ja) | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | 環状化合物およびpparアゴニスト |
WO2003026586A2 (en) | 2001-09-28 | 2003-04-03 | Teva Pharmaceutical Industries Ltd. | Pioglitazone hydrochloride |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
AU2003256419A1 (en) | 2002-08-21 | 2004-03-11 | Merck & Co., Inc. | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist |
EP1637161A4 (en) | 2003-04-22 | 2007-06-27 | Astellas Pharma Inc | MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST |
DK2258349T3 (da) | 2004-05-11 | 2014-10-13 | Egalet Ltd | Kvældbar doseringsform omfattende gellangummi |
PE20060594A1 (es) | 2004-09-09 | 2006-08-18 | Novartis Ag | Composicion farmaceutica que contiene un agonista de ppar |
US20080045580A1 (en) | 2004-10-11 | 2008-02-21 | Dr Reddy's Laboratories Limited | Novel Isoxazole Compounds Having Ppar Agonist Activity |
CN101098690A (zh) | 2004-12-06 | 2008-01-02 | 瑞莱恩特医药品有限公司 | 用于血脂治疗的ω-3脂肪酸和脂血异常剂 |
RU2007131501A (ru) | 2005-01-18 | 2009-02-27 | Новартис АГ (CH) | Способы применения двойных агонистов ppar и устройств для доставки лекарственных средств, содержащих такие соединения |
US20060270722A1 (en) | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
EP1966152A2 (en) | 2005-12-20 | 2008-09-10 | Takeda Pharmaceutical Company Limited | Glucokinase activators |
EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
WO2008063842A2 (en) | 2006-11-02 | 2008-05-29 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with agonists of ppar-gamma |
ES2438768T3 (es) * | 2007-04-11 | 2014-01-20 | Omeros Corporation | Composiciones y métodos para la profilaxis y el tratamiento de adicciones |
-
2010
- 2010-03-11 KR KR1020117023820A patent/KR101767273B1/ko active IP Right Grant
- 2010-03-11 EP EP10708873A patent/EP2405914A1/en not_active Withdrawn
- 2010-03-11 WO PCT/US2010/027048 patent/WO2010105103A1/en active Application Filing
- 2010-03-11 NZ NZ619408A patent/NZ619408A/en unknown
- 2010-03-11 MX MX2011009384A patent/MX2011009384A/es not_active Application Discontinuation
- 2010-03-11 CN CN201710016027.3A patent/CN106692144A/zh active Pending
- 2010-03-11 KR KR1020177021817A patent/KR20170093264A/ko active Search and Examination
- 2010-03-11 CA CA2754901A patent/CA2754901A1/en not_active Abandoned
- 2010-03-11 EP EP18178072.7A patent/EP3398599A1/en active Pending
- 2010-03-11 CN CN2010800114962A patent/CN102348457A/zh active Pending
- 2010-03-11 BR BRPI1009141A patent/BRPI1009141A2/pt not_active Application Discontinuation
- 2010-03-11 NZ NZ595545A patent/NZ595545A/en unknown
- 2010-03-11 AU AU2010224037A patent/AU2010224037B2/en active Active
- 2010-03-11 JP JP2011554216A patent/JP6163289B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
NZ619408A (en) | 2015-08-28 |
CA2754901A1 (en) | 2010-09-16 |
EP3398599A1 (en) | 2018-11-07 |
CN102348457A (zh) | 2012-02-08 |
JP6163289B2 (ja) | 2017-07-12 |
NZ595545A (en) | 2014-02-28 |
AU2010224037B2 (en) | 2015-02-05 |
CN106692144A (zh) | 2017-05-24 |
KR101767273B1 (ko) | 2017-08-10 |
EP2405914A1 (en) | 2012-01-18 |
KR20170093264A (ko) | 2017-08-14 |
WO2010105103A1 (en) | 2010-09-16 |
KR20110127263A (ko) | 2011-11-24 |
MX2011009384A (es) | 2011-10-11 |
AU2010224037A1 (en) | 2011-10-27 |
JP2012520320A (ja) | 2012-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1009141A2 (pt) | composições e métodos para profilaxia e tratamento de vícios | |
BR112012004979A2 (pt) | composições para o tratamento de semente e métodos | |
HK1209056A1 (en) | Treatment or prophylaxis of proliferative conditions | |
EP2141989A4 (en) | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND TREATMENT OF ADDICTIONS | |
EP2603202A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES | |
BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
EP2655334A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
BRPI1008566A2 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
IL220464A (en) | An antidote containing nsaid for topical migraine treatment | |
BRPI1008564A2 (pt) | métodos e composições para o dignóstico e tratamento de câncer | |
BRPI1007600A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
DK3284820T3 (da) | Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger | |
GB0919097D0 (en) | Treatment of hard surfaces | |
IL214455A0 (en) | Methods and compositions for treatment of neovascularization | |
EP2429584A4 (en) | TREATMENT PROCEDURE AND COMPOSITIONS | |
EP2480579A4 (en) | METHODS OF TREATING INFLAMMATION | |
BRPI1013927A2 (pt) | métodos e composições para o tratamento de lúpus | |
GB0902040D0 (en) | Composition for treatment of skin | |
ZA201203239B (en) | Methods and compositions for rapid treatment of otitis externa | |
DK2473482T3 (en) | Methods of treating orthomyxoviral infections | |
BR112012009033A2 (pt) | composições e métodos de profilaxia para dermatite de contato | |
BR112013014915A2 (pt) | composição curativa e métodos de tratamento | |
EP2515652A4 (en) | COMPOSITIONS AND METHODS FOR TREATING VITILIGO |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: OMEROS CORPORATION (US) |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] |